$117 Million

Trillium Therapeutics

Follow-on Offering

Sole Bookrunner, January 2020

Trillium Therapeutics
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Its lead candidate, TTI 621, is a SIRPaFc fusion protein that consists of the CD47 binding domain of human SIRPa linked to the Fc region of a human immunoglobulin G1 (IgG1).